Tabunda, Argie, Jr. N.

HRN: 27-13-70  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/08/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
07/08/2025
07/15/2025
IV
975mg
Q6h
Typhoid Fever; UTI
Pending Pharmacy Acceptance 

 Indication:  Empirical Escalation    Type of Infection:  Urinary TractBloodstream    Compliance to guidelines: